Delaware

Delaware has emerged as a premier destination in the global life sciences ecosystem, renowned for its high concentration of specialized talent and business-friendly environment.

The state is a recognized leader in pharmaceutical R&D and biotechnology innovation, anchored by global giants like AstraZeneca and fast-growing biopharma leaders such as Incyte and Prelude Therapeutics.

Beyond drug discovery, Delaware holds the nation's highest concentration of analytical laboratory instrument manufacturing, making it a critical hub for medical device development and diagnostic technologies.

Strategic public-private partnerships, such as the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) at the University of Delaware, are driving the future of biomanufacturing and workforce training.

The state's healthcare innovation is further bolstered by the Delaware Health Sciences Alliance, which bridges the gap between academic research and clinical application. With world-class facilities like the Delaware Innovation Space providing state-of-the-art wet lab incubator access, startups can scale rapidly within the "Innovation Corridor" connecting New York and Washington, DC.

Furthermore, Delaware's favorable corporate tax structure and R&D tax credits offer unparalleled advantages for life science investment and international incorporation.

This robust infrastructure ensures that the First State remains at the forefront of delivering life-saving biomedical breakthroughs to patients worldwide.